

# Can Serum Procalcitonin Levels Help Interpret Indeterminate Chest Radiographs in Patients Hospitalized With Acute Respiratory Illness?

Edward E. Walsh, MD<sup>1,3\*</sup>, Andrew J. Swinburne, MD<sup>1,3</sup>, Kenneth L. Becker, MD<sup>4</sup>, Eric S. Nylen, MD<sup>4</sup>, Richard H. Snider, MS<sup>4</sup>, Andrea Baran, MS<sup>2</sup>, Derick R. Peterson, PhD<sup>2</sup>, Ann R. Falsey, MD<sup>1,3</sup>

<sup>1</sup>Department of Medicine, University of Rochester, Rochester, New York; <sup>2</sup>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York; <sup>3</sup>Infectious Disease Unit, Rochester General Hospital, Rochester, New York;

<sup>4</sup>Department of Medicine, VA Medical Center and George Washington University, Washington, DC.

**BACKGROUND:** Clinical diagnosis of pneumonia is difficult and chest radiographs often indeterminate, leading to incorrect diagnoses and antibiotic overuse.

**OBJECTIVE:** To determine if serum procalcitonin (ProCT) could assist in managing patients with respiratory illness and indeterminate radiographs.

**DESIGN:** Subjects were prospectively enrolled during 2 consecutive winters.

**SETTING:** A 520-bed hospital in Rochester, NY.

**PATIENTS:** Five hundred twenty-eight adults admitted with acute respiratory illness were enrolled.

**MEASUREMENTS:** Serum ProCT, admission diagnoses, and chest radiographic findings were used to derive

receiver operating characteristics curves to assess predictive accuracy of ProCT for the presence of infiltrates.

**RESULTS:** Subjects with pneumonia had higher ProCT (median 0.27 ng/ml) than those with exacerbations of chronic obstructive pulmonary disease (0.08 ng/ml), acute bronchitis (0.09 ng/ml), or asthma (0.06 ng/ml). ProCT had moderate accuracy for the presence of infiltrates (area under curve [AUC] 0.72), when indeterminate radiographs were independently classified as infiltrates by a pulmonologist evaluating patients.

**CONCLUSIONS:** ProCT may be useful in diagnosing pneumonia when chest radiographs are indeterminate. *Journal of Hospital Medicine* 2013;8:61–67. © 2012 Society of Hospital Medicine

Pneumonia is a common reason for hospitalization and major rationale for administration of antibiotics in the United States.<sup>1</sup> Management guidelines for patients hospitalized with community-acquired pneumonia recommend early antibiotic therapy. Quality measures adopted by the Centers for Medicare and Medicaid Services include antibiotic administration within 6 hours of presentation, based on a relationship between early administration and improved survival.<sup>2–5</sup> However, this imperative has been associated with an increase in incorrect diagnoses of pneumonia.<sup>6,7</sup> While pneumonia diagnosis would seem straightforward, clinical findings frequently do not differentiate pneumonia from other respiratory illnesses. Thus, an infiltrate on chest radiographs (CXR) is commonly used to assign an admitting diagnosis of pneumonia.<sup>8–10</sup> However, radiographic reports are often inconclusive and frequently fail to discriminate pneumonic infiltrates from atelectasis, edema, small pleural effusions, or chronic abnormalities. In cases of uncertainty, physicians invariably initiate anti-

biotics, even when the illness is more consistent with viral bronchitis or asthma, resulting in unnecessary antibiotic use.<sup>6</sup> Previously considered relatively harmless, antibiotic complications can be lethal, and excessive use promotes antimicrobial resistance.<sup>11,12</sup>

Procalcitonin (ProCT), a calcitonin precursor normally produced in the thyroid and lungs, is secreted by cells throughout the body in response to bacterial infections.<sup>13,14</sup> Elevated ProCT is used to screen patients with suspected bacterial infection and predict mortality in critically ill patients.<sup>15,16</sup> Recently, European investigators have used ProCT to guide more selective antibiotic use in patients with symptoms of lower respiratory tract infection (LRTI), including pneumonia.<sup>17–19</sup> However, few reports describe the relationship of ProCT with radiographic features in hospitalized patients with LRTI, and none focus on patients with indeterminate radiographic readings.<sup>18,20,21</sup>

We sought to determine if elevated serum ProCT in adults hospitalized with LRTI symptoms correlates with the clinical diagnosis of pneumonia and definitive infiltrates on CXRs. We specifically assessed ProCT as a diagnostic marker of pneumonia to augment clinical judgment in patients when radiographic findings are indeterminate.

## METHODS

### Subjects

The study was performed in a 520-bed, general medical–surgical hospital, using subjects participating in a

\*Address for correspondence and reprint requests: Edward E. Walsh, MD, Infectious Disease Unit, Rochester General Hospital, 1425 Portland Ave, Rochester, NY 14621; Telephone: 585-922-4331; Fax: 585-922-5168; E-mail: edward.walsh@rochestergeneral.org

Additional Supporting Information may be found in the online version of this article.

Received: May 20, 2012; Revised: August 14, 2012; Accepted: August 26, 2012

2012 Society of Hospital Medicine DOI 10.1002/jhm.1984

Published online in Wiley Online Library (Wileyonlinelibrary.com).

study of the relationship between biomarkers and microbiologic diagnoses (to be described in a separate publication). Adults  $\geq 21$  years of age admitted with a diagnosis compatible with respiratory tract infection (pneumonia, acute exacerbations of chronic obstructive pulmonary disease [AECOPD], acute bronchitis, asthma, upper respiratory infection, viral syndrome, respiratory failure, and congestive heart failure [CHF] with signs of infection) were recruited during winters of 2008–2009 and 2009–2010. Patients were screened within 24 hours of admission; immunosuppression, lung abscess, witnessed aspiration, or previous antibiotic use were exclusion criteria. Blood for ProCT measurement was collected in the emergency room prior to antibiotics. Subjects or legal guardians provided written informed consent, and institutional review boards approved the study.

### Illness Evaluation

At enrollment, demographic, clinical, and laboratory data were collected. To provide consistency of data, 1 investigator (a clinical pulmonary specialist), after interviewing, examining each subject, and considering the radiographic findings, assigned a primary and secondary clinical admitting diagnosis: pneumonia, AECOPD, asthma exacerbation, CHF, acute bronchitis, viral syndrome or influenza, other respiratory illness, or non-respiratory illness. These diagnoses were used for the analysis but were not available to treating physicians. Discharge diagnoses, based on International Classification of Diseases, Ninth Revision (ICD-9) codes, and official results of follow-up chest radiographs were also recorded.

### Radiographic Interpretations

All official admission chest radiographic reports were reviewed by one of the investigators. Radiographic descriptions were noted with attention to the following comments: clear or no acute change from prior radiographs, infiltrates without consolidation, consolidation, edema, atelectasis, and pleural effusion. For our analysis, chest radiographs were categorized into 4 groups: (1) “No acute disease” (NAD) (ie, clear or no change from prior radiographs); (2) “Other” definitive radiographic abnormality (atelectasis, edema, or pleural effusion); (3) “Indeterminate” (findings consistent with pneumonia, but also other processes including atelectasis, edema, scarring but with no favored interpretation [often including the phrase “pneumonia cannot be excluded”]); and (4) “infiltrate” (ie, an infiltrate or consolidation most consistent with pneumonia). The pulmonary specialist independently categorized CXRs and provided a definitive radiographic interpretation whenever possible.

### Microbiology

Blood cultures, sputum Gram stain and culture were performed by the clinical laboratory. Pneumococcal-

specific urinary antigen and serology were performed as previously described.<sup>22</sup>

### Procalcitonin Measurement

Serum ProCT was measured using resolved amplified cryptate emission technology (Kryptor PCT, Brahms, Henningsdorf, Germany). Functional sensitivity is 0.06 ng/mL (normal serum levels are  $0.033 \pm 0.003$  ng/mL).<sup>23–25</sup> ProCT results were not available to investigators at the time of clinical or radiographic assessments.

### Statistical Analysis

Categorical and continuous distributions were compared using Fisher’s exact and Wilcoxon tests, respectively, and summarized by proportions and medians, and means and standard deviations. Log-axis boxplots were used to graphically display the skewed distributions of ProCT. Stacked bar charts were used to depict discrete distributions of diagnoses by ProCT group. Receiver operating characteristic (ROC) curves relating ProCT to chest radiographs were computed, and sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for ProCT thresholds. Logistic regression was used to estimate odds ratios (OR), and associated *P* values and confidence intervals, to quantify associations between infiltrate/non-infiltrate and dichotomized or log-transformed ProCT. SAS 9.2 (SAS Institute, Inc, Cary, NC) was used for analyses, using 2-sided 0.05 level tests.

## RESULTS

### Study Population and Clinical Diagnoses

During 2 winters, 532 subjects admitted for 556 respiratory illnesses were recruited. Two did not have chest radiographs, 16 illnesses were non-pulmonary, and 10 did not have admission ProCT levels, leaving 528 illnesses for analysis (Table 1). Subjects averaged 65 years of age, predominately lived at home, and a high percentage had underlying diseases. The leading primary admission diagnoses assigned by the pulmonologist were pneumonia and AECOPD at 31% and 27%, respectively. Of the 163 illnesses assigned a primary or secondary admitting diagnosis of pneumonia, infiltrates were identified on the admission radiograph by the pulmonologist in 156 (96%).

### Radiographic Classifications

Based on radiology reports, 213 (40%) were classified as NAD, 76 (14%) as “other” definitive findings, 75 (14%) as infiltrates, and 164 (31%) as indeterminate. The pulmonologist concurred with the radiology report for most NAD (199/213) and infiltrate (67/75) classifications, but only 4 as indeterminate, assigning approximately half the radiologist’s indeterminate CXRs to infiltrate and one-quarter each to NAD and “other” categories.

**TABLE 1.** Clinical Characteristics of Study Population

	Illnesses N = 528 (%)
Age (mean ± SD)	65 ± 17
Female	278 (53)
Race	
White	409 (77)
African American	119 (23)
Hispanic	53 (10)
Residence	
Community	488 (92)
Assisted living	27 (5)
Nursing home	13 (2)
Medical conditions	
Diabetes	188 (36)
CHF	153 (29)
COPD	216 (41)
Chronic renal failure	21 (4)
Past or active smoker	395 (75)
Current influenza vaccine	371 (70)
Prior pneumococcal vaccine	432 (82)
Oral steroids	69 (13)
Inhaled steroids	201 (38)
Home oxygen	129 (24)
Symptoms, No. (%)	
Upper respiratory	350 (66)
Cough	489 (93)
Sputum production	390 (74)
Dyspnea	496 (94)
Wheezing	345 (65)
Constitutional	271 (51)
Feverish	293 (55)
Rigors	118 (22)
Physical exam	
Wheezing	279 (53)
Rales	211 (40)
Rhonchi	144 (27)
Temperature (mean ± SD)	37.2 ± 1.0
Respiratory rate (mean ± SD)	25 ± 7
Laboratory data	
Oxygen saturation (mean ± SD)	92.3 ± 5.5
WBC × 10 <sup>3</sup> /ml (mean ± SD)	9.4 ± 4.8
Clinical diagnosis	
Pneumonia	163 (31)
Asthma	76 (14)
CHF	45 (9)
Bronchitis	83 (16)
AECOPD	142 (27)
Other pulmonary	19 (4)
Therapy	
Antibacterials	463 (88)
Antivirals	38 (7)
Outcome	
Intensive care	43 (8)
Respiratory failure	29 (6)
Death	6 (1)
Length of stay (mean ± SD)	5.9 ± 18.7

Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; SD, standard deviation; WBC, white blood cells.

### Relationship of ProCT With Clinical and Radiographic Features

The relationship between clinical admitting diagnosis and ProCT is shown in Figure 1A. Subjects with pneu-


monia had a median ProCT of 0.27 ng/ml (interquartile range [IQR] 1.3), significantly greater than subjects with AECOPD, asthma, acute bronchitis, and viral/influenza. Subjects assigned to the “other” diagnoses category (ie, skin or urinary infections, empyema) generally had higher ProCT values (median 0.70 ng/ml, IQR 4.6).

The relationship between the radiologist’s classification and ProCT is shown in Figure 1B. Median ProCT levels were significantly lower in subjects with radiographs classified as NAD compared to those showing infiltrates ( $P < 0.0001$ ). Those classified as indeterminate in radiology reports had a median ProCT value (0.13 ng/ml) midway between those with NAD (0.08 ng/ml) and infiltrates (0.21 ng/ml). Similarly, illnesses with radiographs classified by the pulmonologist as infiltrates also had significantly higher median ProCT levels (0.33 ng/ml, IQR 1.33) than those classified as NAD (0.08 ng/ml, IQR 0.06;  $P < 0.0001$ ), and other definitive findings (0.11 ng/ml, IQR 0.17). Notably, duration of symptoms prior to evaluation did not affect the relationship between ProCT level and radiographic classification (data not shown). All subjects with infiltrates according to the radiologist’s report received early antibiotics, as did 97% and 80% with indeterminate radiographs and NAD, respectively.

### Predictive Value of ProCT for Interpreting Indeterminate Radiographs

We were specifically interested to learn if ProCT could help clinicians interpret the large number of indeterminate radiographs. As a first step, we evaluated the diagnostic accuracy of ProCT for radiographic infiltrates by calculating the ROC curve (Figure 2A), using cases in which radiologist and pulmonologist concurred on the classification as infiltrate ( $n = 67$ ) or no infiltrate (ie, NAD or other definitive finding;  $n = 273$ ). For these cases, the ROC had an area under curve (AUC) of 0.80 ( $P < 0.0001$ ), indicating moderate predictive accuracy of ProCT for the presence of an infiltrate. The OR for an infiltrate increased steadily with higher ProCT thresholds, quadrupling from 3.9 to 15.6 as the threshold increased from 0.05 to 0.50 ng/ml (Table 2). Using the commonly defined 0.25 ng/ml ProCT threshold for which antibiotics have been recommended for respiratory infections, the PPV for an infiltrate was 61% and the NPV 89%.

Next, we analyzed the 164 illnesses with indeterminate radiographs. Of these, the pulmonologist classified 79 as infiltrate (median ProCT 0.29 ng/ml), 40 as NAD (median ProCT 0.08 ng/ml), 41 as other definitive findings (median ProCT 0.10 ng/ml), and 4 as indeterminate. The admitting diagnosis and corresponding median ProCT for these subjects was pneumonia in 78 (0.28 ng/ml), AECOPD in 26 (0.09 ng/ml), acute bronchitis in 30 (0.09 ng/ml), asthma in 11 (0.08 ng/ml), and CHF in 14 (0.10 ng/ml). The ROC AUC for these cases (excluding 4 considered indeterminate by the




**FIG. 1.** Logarithmic axis boxplots of serum procalcitonin (ProCT) with medians, quartiles, minima, and maxima (whiskers), and means ( $\diamond$ ) by (A) admitting diagnosis;  $P < 0.0001$  for pneumonia vs AECOPD, asthma, and bronchitis;  $P = 0.02$  for pneumonia vs viral/flu; and (B) according to chest radiograph interpretation on the official radiology report.  $P < 0.0001$  for infiltrate vs NAD and other;  $P = 0.003$  for infiltrate vs indeterminate. Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CHF, congestive heart failure; NAD, no acute disease.

pulmonologist) was slightly lower (0.72,  $P < 0.0001$ ) than the prior analysis (Figure 2B), but ProCT retained moderate predictive value for the presence of infiltrates as diagnosed by the pulmonologist on indeterminate radiographs (Table 3).

Since clinical determinations by a single pulmonologist may be subjective, we sought to objectively assess

the accuracy of assigned admission diagnoses by analyzing additional data, including bacterial tests, follow-up radiographs, and final discharge diagnoses. As a surrogate of invasive bacterial infection, we used identification of *S. pneumoniae* as the outcome, since multiple complementary diagnostic assays were used, thus minimizing the uncertainty of sputum cultures.



**FIG. 2.** Receiver operating characteristic (ROC) curves for procalcitonin (ProCT) for (A) cases in which the radiologist and pulmonologist's radiographic interpretation were in agreement for definitive infiltrate ( $n = 67$ ) or non-infiltrate (NAD or other definitive change;  $n = 273$ ); and (B) for 160 indeterminate radiographs using pulmonologist's classification as infiltrate ( $n = 79$ ) or no infiltrate ( $n = 81$ ) as the final determination. Abbreviations: AUC, area under curve; NAD, no acute disease.

Overall, we identified 58 pneumococcal infections (Table 4). The pulmonologist's admitting diagnosis of pneumonia captured a higher proportion (52% for any test positive) of *S. pneumoniae* cases than identification of a radiographic infiltrate by the radiologist (26%), and equivalent to the pulmonologist's radiographic reading (57%) or elevated ProCT alone (57%). There was an absolute 14% increase (27% relative increase) in the detection of *S. pneumoniae* infec-

**TABLE 2.** Sensitivity, Specificity, and OR at Each ProCT Threshold for Cases in Which Radiologist and Pulmonologist Concurred as Showing Either Infiltrate or No Infiltrate

ProCT Threshold (ng/ml)	Sensitivity (%)	Specificity (%)	OR	P Value
0.05	94	20	3.9	0.012
0.07	90	42	6.1	<0.0001
0.10	79	65	7.1	<0.0001
0.12	73	72	7.1	<0.0001
0.15*	67	82	9.1	<0.0001
0.20	58	88	10.5	<0.0001
0.25	52	92	12.5	<0.0001
0.50	42	96	15.6	<0.0001

Abbreviations: OR, odds ratio; ProCT, procalcitonin. \*ProCT threshold of 0.15 is approximately optimal, maximizing sensitivity + specificity (minimizing expected error rate).

tions by addition of ProCT to the pulmonologist's diagnosis. A similar analysis limited to the 164 subjects with indeterminate radiographs found that 13 of 19 (68%) of *S. pneumoniae* diagnoses had been assigned a clinical diagnosis of pneumonia by the pulmonologist.

We also determined how often subsequent radiographs showed evolution to a definitive infiltrate in indeterminate cases that the pulmonologist had classified as either NAD or "other" finding. Only 3/20 with repeat films showed a definitive infiltrate, none of whom had evidence of bacterial infection, and all 3 had ProCT <0.25 ng/ml. In contrast, 10 of 21 subjects with indeterminate CXRs, that the pulmonologist had classified as an infiltrate, developed definitive infiltrates on follow-up studies ( $P = 0.04$ ), and 8 remained indeterminate.

Finally, 93% of those assigned an admitting pneumonia diagnosis by the pulmonologist had primary (71%) or secondary (22%) discharge diagnosis of pneumonia. Of the additional 28 subjects with a discharge diagnosis of pneumonia, for whom the pulmonologist assigned non-pneumonia admitting diagnoses, none had positive blood cultures or evidence of *S. pneumoniae* infection, and only one had a follow-up radiograph showing a definitive infiltrate.

## DISCUSSION

Pneumonia can be a serious illness and, if left untreated, result in death. Hence, infectious disease and pulmonary societies advocate timely administration of antibiotics. Unfortunately, clinical diagnosis of pneumonia is difficult, as clinical and radiographic features are often ambiguous. These factors result in liberal use of broad-spectrum antibiotics, often in patients with viral infection, in whom antibiotic side effects outweigh benefit.<sup>26</sup> Although pneumonia guidelines recommend early antibiotic therapy for patients with infiltrates on CXR, we found that early administration of antibiotics for "possible" pneumonia is nearly universal.<sup>2,27</sup> Thus, an objective laboratory test

**TABLE 3.** Sensitivity, Specificity, PPV, NPV, OR, and Predicted Probability of Infiltrate as Functions of ProCT Thresholds, Based on the CXR-Indeterminate Data

ProCT Threshold	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	OR	P Value	Predicted Probability (%)
0.05	95	7	50	60	1.5	0.54	32
0.07	86	27	54	67	2.3	0.04	35
0.10	80	59	66	75	5.7	<0.0001	40
0.12*	76	67	69	74	6.3	<0.0001	42
0.15	67	74	72	70	5.8	<0.0001	45
0.20	63	78	74	69	6.0	<0.0001	49
0.25	53	80	72	64	4.6	<0.0001	52
0.50	37	88	74	59	4.1	0.0006	60

NOTE: Probabilities of infiltrate at each ProCT threshold based on univariate logistic regression model for infiltrate as function of continuous  $\log_2(\text{ProCT})$ ; corresponding OR = 1.4 (1.2, 1.7) per doubling of ProCT ( $P < 0.0001$ ). Abbreviations: CXR, chest radiographs; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; ProCT, procalcitonin. \*ProCT threshold of 0.12 was optimal and maximized the likelihood (and OR) over all thresholds and minimized the error rate.

**TABLE 4.** *S. pneumoniae* Infections Captured by Criteria Listed, According to Diagnostic Assay

Criteria	<i>S. pneumoniae</i> Confirmed by Diagnostic Assay No. (%)				
	Blood Culture + (n = 7)	Urine Ag + (n = 27)	Serology + (n = 28)	Sputum + (n = 20)	Any Test + (n = 58)
Radiologist CXR read as "infiltrate"	3 (43)	9 (33)	10 (36)	3 (15)	15 (26)
Pulmonologist CXR read as "infiltrate"	6 (86)	17 (62)	18 (64)	10 (50)	33 (57)
Pulmonologist clinical diagnosis of pneumonia	6 (86)	16 (60)	16 (57)	8 (40)	30 (52)
Pulmonologist clinical diagnosis of AECOPD	0 (0)	4 (15)	5 (18)	5 (25)	8 (14)
Procalcitonin $\geq 0.25$ ng/ml	6 (86)	18 (67)	17 (61)	9 (45)	33 (57)
Pulmonologist diagnosis of pneumonia and/or ProCT $\geq 0.25$ ng/ml	7 (100)	19 (70)	20 (71)	10 (50)	38 (66)

Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CXR, chest radiographs; ProCT, procalcitonin.

indicative of pneumonia would be a useful adjunct when making treatment decisions.

In an attempt to curb excessive antibiotic use, European investigators have used ProCT to guide therapy for respiratory tract infection, including pneumonia, without increased adverse outcomes.<sup>17,19,28,29</sup> Antibiotics are recommended when ProCT levels are  $\geq 0.25$  ng/ml, rather than based on radiographic or microbiological results. However, ProCT-guided antibiotic management has not been adopted in the United States, and radiographic findings are a major determinant for diagnosis of pneumonia and antibiotic administration.

Thus, we were interested in correlating ProCT levels with the presence of radiographic infiltrates, and especially how ProCT could assist in interpreting the vexing problem of indeterminate CXRs. We found a direct relationship between an increased ProCT level and definitive infiltrates on CXR, similar to results reported by others.<sup>18,20,21</sup> However, these studies did not address illnesses with indeterminate radiographs, which accounted for approximately one-third of the radiologist's readings in our study. Our situation is likely not unique. In a post hoc analysis of CXRs from subjects with "pneumonia" in the PORT study, independent radiologists interpreted a similar proportion of CXRs as either no acute disease or possible infiltrates.<sup>30</sup> Since indeterminate readings include the possibility of an infiltrate, it is not surprising that 97% of our subjects received early antibiotic treatment.

Given current pneumonia treatment guidelines, ProCT testing for those with *definitive* infiltrates would not add to patient management, as all should receive early antibiotics. However, ProCT measurement could have significant impact on management in those with indeterminate films. We found ProCT was moderately predictive for infiltrates when utilizing the pulmonologist's interpretation of indeterminate CXRs. This is concordant with a recent study reporting a similar ROC (0.72) for ProCT for diagnosing pneumonia in patients with dyspnea, and more predictive of pneumonia than any clinical variable.<sup>31</sup>

The major limitation of our study is the lack of a "gold" standard for diagnosis of pneumonia. We chose to use a pulmonary specialist to provide admission diagnoses, and independently interpret radiographs in the context of clinical findings. Although imperfect, we feel this approach best reflects good medical practice by an experienced clinician evaluating the CXR in context of a patient's history and physical exam. Importantly, analysis of the concurrent microbiology data, follow-up radiographs, and discharge diagnoses supports the accuracy of the admitting diagnoses of pneumonia and radiographic interpretations by the pulmonologist. Secondly, our findings may not be applicable to immunocompromised or previously treated patients.

How should a busy physician respond to a patient with dyspnea and fever when faced with an indeterminate radiographic report, since no method for the diagnosis of pneumonia is infallible?<sup>8,32</sup> Clearly, a

pulmonary consultation on all such patients is impractical. Our data confirms previous results that high ProCT values are correlated with an infiltrate on CXR and low values have a NPV of nearly 90%. Furthermore, low ProCT values predict low mortality across all levels of standard severity scoring indexes.<sup>33</sup> Thus, a low ProCT may help clinicians feel more confident to delay or stop antibiotics in a patient in whom clinical suspicion for bacterial pneumonia is low, yet the radiographic report states “pneumonia cannot be ruled out.”<sup>34</sup> Such strategies may assist in reducing unnecessary antibiotic use in the United States.<sup>35</sup>

Disclosures: Funding for this study was provided by NIAID-1R01AI079446-01. This work was presented in part at the Infectious Diseases Society of America, Boston, MA, October 2011. The authors report no conflicts of interest.

## References

- Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. *Clin Infect Dis*. 2004;39:1642–1650.
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44(suppl 2):S27–S72.
- Centers for Medicare and Medicaid Services. The Medicare national pneumonia quality improvement project. Available at: <http://www.cms.gov/HospitalQualityInits/>. Accessed September 8, 2011.
- Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. *Arch Intern Med*. 2004;164:637–644.
- Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. *JAMA*. 1997;278:2080–2084.
- Kanwar M, Brar N, Khatib R, Fakhri MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. *Chest*. 2007;131:1865–1869.
- Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. *Arch Intern Med*. 2008;168:351–356.
- Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. *Am J Med*. 2004;117:305–311.
- Boersma WG, Daniels JM, Lowenberg A, Boeve WJ, van de Jagt EJ. Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. *Respir Med*. 2006;100:926–932.
- Hagaman JT, Rouan GW, Shipley RT, Panos RJ. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. *Am J Med Sci*. 2009;337:236–240.
- Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. *Clin Infect Dis*. 2011;52:1232–1240.
- Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. *Clin Infect Dis*. 2008;46:155–164.
- Becker KL, Nylén ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab*. 2004;89:1512–1525.
- Becker KL, Snider R, Nylén ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. *Crit Care Med*. 2008;36:941–952.
- Becker KL, Snider R, Nylén ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. *Br J Pharmacol*. 2010;159:253–264.
- Nylén ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. *Am J Med Sci*. 1996;312:12–18.
- Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. *Chest*. 2007;131:9–19.
- Holm A, Pedersen SS, Nexøe J, et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. *Br J Gen Pract*. 2007;57:555–560.
- Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA*. 2009;302:1059–1066.
- Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. *Chest*. 2011;139:1410–1418.
- Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. *BMC Infect Dis*. 2008;7:10.
- Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. *Int J Chron Obstruct Pulmon Dis*. 2011;7:127–135.
- Snider RH Jr, Nylén ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. *J Invest Med*. 1997;45:552–560.
- Nylén E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. *Clin Infect Dis*. 2003;36:823–824.
- Bihan H, Becker KL, Snider RH, et al. Calcitonin precursor levels in human medullary thyroid carcinoma. *Thyroid*. 2003;13:819–822.
- Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. *Clin Infect Dis*. 2008;47:735–743.
- Mandell L, Wunderink R, Anzueto A, et al. Guideline tyranny: a response to the article by Baum and Katsas. *Clin Infect Dis*. 2008;47:1117–1118.
- Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. *Am J Respir Crit Care Med*. 2006;174:84–93.
- Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. *Lancet*. 2004;363:600–607.
- Albaum MN, Hill LC, Murphy M, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT investigators. *Chest*. 1996;110:343–350.
- Maisel A, Neath S-X, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. *Eur J Heart Fail*. 2012;14:278–286.
- Chandra A, Nicks B, Maniago E, Nouh A, Limkakeng A. A multicenter analysis of the ED diagnosis of pneumonia. *Am J Emerg Med*. 2010;28:862–865.
- Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. *Eur Respir J*. 2008;31:349–355.
- Metersky ML, Sweeney TA, Getzow MB, Siddiqui F, Nsa W, Bratgier DW. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? *Chest*. 2006;130:16–21.
- Fowler CL. Procalcitonin for triage of patients with respiratory tract symptoms: a case study in the trial design process for approval of a new diagnostic test for lower respiratory tract infection. *Clin Infect Dis*. 2011;52(S4):S351–S356.